Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

3SBio Receives $337 Million Go-Private Offer

publication date: Sep 12, 2012
3SBio, a China biotech, received an offer to take the company private at a price of $15 per share, a transaction that values the company at $337 million. The offer was made by Dr. Jing Lou, 3SBio’s Chairman and CEO, along with CPEChina Fund LP, a Cayman Island entity associated with CITIC Private Equity Fund. The offer was priced at a 32% premium to yesterday’s closing price of $11.39. In today’s trading, 3SBio rose $1.84 to $13.43, a 16% increase. Even at the buyout price, 3SBio has a lot of value. More details....

Stock Symbol: (NSDQ: SSRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital